© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
Examining the Use of Immunoglobulin for Primary Immunodeficiency Disorders
This continuing education activity is supported by an educational grant from CSL Behring.
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM CSL BEHRING.
FACULTY
Luigi Brunetti, PharmD, MPH
Associate Professor of Pharmacy, Co-Director, Center of Excellence in Pharmaceutical Translational Research
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey
At the completion of this activity, the participant will be able to:
- Explain the pathophysiology of common primary immunodeficiency disorders (PIDs)
- Analyze the use of intravenous (IV) and subcutaneous (SC) immunoglobulins for PID, including dosing, efficacy, and unique characteristics of products
- Identify pharmacy considerations for IV and SC initiation, administration, and adverse effect management
TARGET AUDIENCE: Specialty pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: March 30, 2020
EXPIRATION DATE: June 14, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at www.pharmacytimes.org.